News
The U.S. Department of Veterans Affairs is taking aim at homelessness and its related issues affecting America's veteran ...
2d
Cryptopolitan on MSNRipple sets bold five-year target to capture SWIFT transaction volume with XRPRipple CEO Brad Garlinghouse has predicted that XRP could take up to 14% of interbank messaging platform SWIFT transaction volume in the next five years. Garlinghouse shared this projection at the ...
Merus initially surged on superior interim trial data, while Bicara Therapeutics tanked. Click here to find out why BCAX ...
Rhythm Technologies, Inc.'s Q1 2025 growth, AI innovations, and market expansion. Click for why I upgraded IRTC to Buy ...
11h
The Nation UAE on MSNDigital smear campaigns threaten IT industry progressPakistan's technology industry, once gaining traction through innovation, talent, and startup grit, is now facing a very different kind of challenge. At first glance, the problem might appear to stem ...
Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further devel ...
WASHINGTON — Trump administration officials are expected to release more details on their plan to lower prescription drug ...
President Trump told reporters this week that he would send letters to trading partners in the next week or two setting ...
Tesla ( TSLA 5.66%) stock has tumbled 22% year to date amid a myriad of business and political headwinds, and Wall Street ...
TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response alongside pembrolizumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results